Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose

뉴스 본문을 불러오고 있어요.

Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose | 웨이프 WAPE

Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose

기사 요약

관련 종목

댓글 —